HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Targeted therapies in cancer represent a significant advancement in the field of oncology, offering a more precise and personalized approach to treatment. Unlike traditional chemotherapy, which affects rapidly dividing cells indiscriminately, targeted therapies aim to interfere with specific molecules involved in the growth and survival of cancer cells. This targeted approach not only enhances the therapeutic efficacy but also minimizes damage to healthy cells, reducing the side effects commonly associated with conventional treatments.
One key category of targeted therapies includes small molecule inhibitors that block the activity of specific proteins involved in cancer progression. Tyrosine kinase inhibitors, for example, interfere with the signaling pathways that drive cell growth, and are used in various cancers such as breast, lung, and gastrointestinal cancers. Monoclonal antibodies are another type of targeted therapy that can recognize and bind to specific proteins on the surface of cancer cells, marking them for destruction by the immune system. These antibodies have proven effective in the treatment of cancers like breast, colorectal, and lymphomas.
Precision medicine plays a crucial role in the development and application of targeted therapies. Molecular profiling of tumors helps identify specific genetic or molecular alterations that drive cancer growth. By understanding the unique characteristics of an individual's cancer, oncologists can select targeted therapies that are more likely to be effective, leading to improved outcomes and reduced treatment-related toxicities.
